Tumor Necrosis Factor-alpha (TNF-α)

TNF-α is a signaling protein (a cytokine) released by immune cells, especially macrophages, that drives inflammation throughout the body. It helps the body fight infection and damaged cells, but when it stays elevated for long periods it can promote chronic inflammation, tissue scarring, and conditions that favor cancer development.

Origin

TNF was first described in 1975 by Lloyd Old and colleagues at Memorial Sloan Kettering as a substance in the blood of animals that caused certain tumors to shrink and die ("necrose"). The protein was cloned in 1984, and "alpha" was added to distinguish it from a related cytokine, lymphotoxin (TNF-β).

Significance in Asbestos Context

When asbestos fibers lodge in lung or pleural tissue, immune cells called macrophages try to engulf them but cannot break them down. These frustrated macrophages release TNF-α repeatedly, decade after decade. This sustained TNF-α release is now understood to be a key driver of asbestos-related disease: it promotes the scarring seen in asbestosis and pleural plaques, and, critically for mesothelioma, it helps injured mesothelial cells survive and multiply when they would normally die, giving damaged cells time to accumulate the genetic changes that lead to cancer. Patients may see TNF-α mentioned in expert reports explaining the biological mechanism (the "how") of how their asbestos exposure caused their disease, which is often important in legal proceedings.

Example Sentence

The plaintiff's pulmonologist explained that asbestos fibers trapped in the pleura trigger ongoing TNF-α release, a mechanism well established in the scientific literature as a pathway from fiber exposure to mesothelioma.

Related Terms

Cytokine, Macrophage, Chronic Inflammation, HMGB1, Mesothelioma, Asbestosis

Notes

• If you are reviewing an expert causation report, look for discussion of TNF-α and HMGB1. These are the two molecules most often cited to explain how asbestos fibers biologically cause mesothelioma and other diseases.
• Ask your oncologist whether any clinical trials in your area are testing anti-inflammatory or immune-modulating drugs (including TNF-α pathway agents) for mesothelioma; trial eligibility can change quickly.
• If you take a TNF-α inhibitor (such as infliximab, adalimumab, or etanercept) for an unrelated condition like rheumatoid arthritis or Crohn's disease, tell every doctor treating your asbestos-related disease, because these drugs alter immune surveillance and can affect cancer treatment decisions.
• Preserve copies of any blood work or pathology reports that mention inflammatory markers. These can support the biological-mechanism portion of a legal claim.